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C A N C E R
A live single-cell reporter assay links intratumor 
heterogeneity to metastatic proclivity in Ewing sarcoma
Tugba Keskin1, Beatrice Rucci1, Sandrine Cornaz-Buros1, Patricia Martin1, Carlo Fusco1, 
Liliane Broye1, Katarina Cisarova2, Elizabeth M. Perez3,4,5, Igor Letovanec6,7, Stefano La Rosa7, 
Stephane Cherix8, Manuel Diezi9, Raffaele Renella9, Paolo Provero10, Mario L. Suvà3,4, 
Ivan Stamenkovic1*†, Nicolò Riggi1†
Targeting of the most aggressive tumor cell subpopulations is key for effective management of most solid 
malignancies. However, the metastable nature of tumor heterogeneity, which allows cells to transition between 
strong and weak tumorigenic phenotypes, and the lack of reliable markers of tumor-promoting properties hamper 
identification of the most relevant cells. To overcome these obstacles, we designed a functional microRNA (miR)–
based live-cell reporter assay to identify highly tumorigenic cells in xenotransplants of primary Ewing sarcoma 
(EwS) 3D cultures. Leveraging the inverse relationship between cell pluripotency and miR-145 expression, we 
successfully separated highly tumorigenic, metastasis-prone (miR-145low) cells from poorly tumorigenic, non-
metastatic (miR-145high) counterparts. Gene expression and functional studies of the two cell populations identified 
the EPHB2 receptor as a prognostic biomarker in patients with EwS and a major promoter of metastasis. Our study 
provides a simple and powerful means to identify and isolate tumor cells that display aggressive behavior.
INTRODUCTION
One of the greatest challenges to cancer therapy is the effective 
targeting of cells that provide the driving force to the growth and 
progression of any given tumor. Despite the long-standing notion 
that solid tumors are heterogeneous, most of the conventional cyto-
toxic drug–based strategies, which still dominate anticancer treat-
ment, do not account for target cell heterogeneity and have reached 
their limit in terms of efficacy. Identification and detailed molecular 
characterization of tumor-driving cells along with in-depth under-
standing of the dynamics that govern their phenotype therefore 
appear to be inescapable requirements for the design of effective 
anticancer treatment.
Several mechanisms underlie the heterogeneity that characterizes 
solid malignancies, most prominent among which are clonal selec-
tion and hierarchical organization of tumor cells along with the 
effects of microenvironmental cues (1–3). Tumor cell plasticity 
renders the heterogeneity dynamic by allowing cells that drive tumor 
growth to differentiate and lose their tumorigenic properties in 
addition to providing the means for nontumorigenic cells to regain 
tumor-initiating capability (2–4). It is also key to tumor cell adaptation 
and resistance to treatment (2, 4, 5). Comprehensive identification 
of individual cells and cell subpopulations endowed with the ability 
to initiate and maintain tumor growth and progression is hampered 
by their lack of reliable biological markers. Although some cell 
surface receptors have been useful in isolating cell populations en-
riched in tumor-initiating cells (1, 6), their ability to identify the full 
spectrum of cells that drive any given tumor remains limited. More-
over, because cancer cells, at least in some tumor types, may transi-
tion between tumorigenic and nontumorigenic phenotypes (1, 7), it 
stands to reason that any unbiased approach designed to capture 
them in their tumorigenic state should exploit mechanisms under-
lying their plasticity in the most appropriate models available.
The recent development of three-dimensional (3D) culture tech-
nologies has facilitated assessment of tumor heterogeneity and drug 
sensitivity in a relevant preclinical setting. Under appropriate culture 
conditions, tumor-derived primary cells can generate spheroids that 
retain the native tissue heterogeneity or, as observed in a variety of 
carcinomas, organoids, which recapitulate both the heterogeneity 
and architecture of the tissue of origin (8–10). Primary 3D cultures 
derived from a variety of cancer types have helped identify major 
determinants of tumor heterogeneity and uncover therapeutic 
vulnerabilities that went unrecognized in standard 2D models (10, 11). 
Moreover, patient-derived tumor 3D culture xenografts (PDXs) 
currently provide the closest in vivo mimics of the corresponding 
native tumors (12) and are particularly valuable for the study of 
cancers that lack genetically engineered mouse models. A case in 
point is Ewing sarcoma (EwS), the second most common bone 
malignancy in children and young adults (13).
EwS is a highly aggressive tumor with a marked tendency to 
relapse following therapy as well as high metastatic proclivity (14). 
Although multimodal therapy has improved survival of patients with 
localized disease, metastatic lesions at diagnosis markedly worsen 
prognosis, reducing the 5-year survival to 25%. EwS is caused by 
one of several reciprocal chromosomal translocations leading to the 
formation of a fusion a gene that encodes an aberrant transcription 
factor, the most common, found in 85 to 90% of tumors, being 
EWS-FLI1 (15). The chromosomal translocation is the only detect-
able genetic event in about 25% of EwS, suggesting that the resulting 
fusion protein bears dominant, if not sole, responsibility for their 
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pathogenesis. EWS-FLI1 behaves as an aberrant transcriptional reg-
ulator that orchestrates major chromatin remodeling and functions 
as a pioneer factor to establish de novo active enhancers at GGAA 
microsatellite repeats (16). It promotes cell plasticity by deregulating 
microRNA (miRNA) maturation (17) and by directly decreasing 
miR-145 expression, which plays a prominent role in limiting cell 
pluripotency in both normal development and cancer (18, 19). 
Repression of miR-145 contributes to the emergence and maintenance 
of poorly differentiated cells, which not only initiate primary and 
metastatic tumor growth but also differentiate into nontumorigenic 
progeny, thereby fueling tumor heterogeneity (17–19).
Here, we devised an experimental approach combining the power 
of miRNA reporter technology with primary 3D models of EwS to 
identify tumor cell subpopulations endowed with high tumorigenic 
and prometastatic properties. We leveraged the relationship between 
down-regulation of miR-145 and increased tumor cell pluripotency 
in EwS (18) to generate an inducible reporter system and isolate live 
primary miR-145high and miR-145low tumor cells in vivo. Functional 
analyses showed miR-145low cells to be far more tumorigenic than 
their miR-145high counterparts and to display a distinct gene expression 
signature comprising several oncogenes, including the receptor tyro-
sine kinase (RTK) EPHB2 (Ephrin type-B receptor 2). Current databases 
show EPHB2 expression to be associated with poor survival among 
patients with EwS, and our functional assays revealed that EPHB2 plays 
a critical role in promoting metastasis in EwS. On the basis of the role 
played by miR-145 in the emergence of undifferentiated and aggressive 
cells in other tumors, we anticipate our inducible in vivo reporter assay 
to be widely applicable to diverse cancer types and to facilitate the de-
sign of mechanism-based strategies to defeat tumor heterogeneity.
RESULTS
Detection of miR-145 activity in primary EwS cells
Our working strategy is summarized in Fig. 1A. Briefly, primary 3D 
tumor cell cultures from EwS removed at surgery were engineered 
to express the miR-145 reporter. Following validation of reporter 
activity in vitro, the 3D culture–derived tumor cells were trans-
planted into immunocompromised mice, the resulting tumors were 
removed, and cells were sorted based on reporter activity. Cells with 
high and low miR-145 expression could then be assessed for gene 
expression, clonogenicity, and tumor-initiating capacity following 
reinjection into mice.
To develop an inducible miR-145 responsive reporter (mirRep145), 
we engineered a green fluorescent protein (GFP)–encoding se-
quence containing five consecutive miR-145 recognition motifs 
in its 3´ untranslated region (3´UTR) and inserted it into the 
pINDUCER20 plasmid, downstream of the TRE2 promoter (Fig. 1A 
and fig. S1A) (20). An inducible, tetracycline-activated (Tet-On) 
expression system was chosen to minimize the potential sponge 
effect of exogenous miRNA binding site overexpression. Adminis-
tration of doxycycline (Dox) to the cells harboring mirRep145 
induced transcription of the GFP reporter sequence, and GFP ex-
pression levels were directly dependent on the intrinsic miR-145 
activity (by binding to its target sequences, miR-145 suppresses the 
translation or transcription of the corresponding gene), providing 
an unbiased means to identify miR-145low (GFP+) and miR-145high 
(GFP−) cells (Fig. 1A). miR-145 target sequences were substituted 
by an unrelated DNA sequence to generate a mirReporter-Control 
vector (mirRepC) (fig. S1B).
mirRep145 was tested in HeLa cells, which express low levels of 
miR-145. Induction of GFP expression in cells harboring mirRep145 
occurred within 48 hours of treatment with Dox, as assessed by con-
focal microscopy (Fig. 1B and fig. S1C, bottom), and neither 
mirRep145- nor mirRepC-containing cells expressed GFP in the 
absence of Dox (Fig. 1B and fig. S1C, top). To validate the specific 
dependency of our reporter system on miR-145 activity, we tested 
the effect of unrelated miRNAs on HeLa cells bearing mirRep145 
using expression plasmids containing the red fluorescent protein 
(RFP)–puromycin resistance fusion protein (rPuro), which allows 
simultaneous assessment of infection efficiency by RFP expression 
and selecting for puromycin resistance (Fig. 1C, middle). Immuno-
fluorescence microscopy of Dox-treated HeLa mirRep145 cells 
infected with a mock miRNA sequence (an unrelated sequence 
matching miR-145 length), let7a-, or miR-145–containing vectors 
revealed reduced GFP expression only in cells expressing miR-145 
(Fig. 1C, right), indicating specific targeting of the reporter GFP 
construct by miR-145.
We then assessed mirRep145 function in two EwS 3D cultures, 
EwS1 and EwS2 (21–23), derived, respectively, from a metastatic lung 
lesion removed after chemotherapy and an untreated primary tumor 
(table S1). Both 3D cultures, which appeared as spheroids, retained 
the hierarchical cellular organization of the primary tumors from 
which they were derived (21, 22). EwS1 and EwS2 cells infected with 
a lentivirus containing the mirRep145 were maintained as 3D cul-
tures in medium supplemented with Dox for 48 hours and assessed 
for GFP expression by flow cytometry and fluorescence microscopy 
2 (D2), 5 (D5), and 10 (D10) days following Dox removal (fig. S1, 
D to G). Fluorescence-activated cell sorting (FACS) revealed that 
47 and 38% of the EwS1- and EwS2-mirRep145 cell populations, 
respectively, were GFP+ after Dox-mediated induction (fig. S1, D 
and F). GFP expression decreased rapidly following Dox removal and 
was undetectable after 10 days of Dox-free culture. Neither Dox nor its 
removal affected 3D spheroid formation in vitro (fig. S1, E and G).
Purification of primary EwS cell subpopulations based 
on miR-145 expression
We previously showed that EwS cells with low miR-145 expression 
have clonogenic and tumor-initiating capacity, giving rise to tumors 
that phenocopy the original tumor, whereas cells with high miR-145 
expression from the same tumor were poorly tumorigenic (17, 18). 
To address the properties of miR-145low EwS cells and identify can-
didate predictive markers of tumor aggressiveness, we transplanted 
mirRep145-expressing EwS1 and EwS2 3D culture–derived cells into 
the subcapsular renal compartment of nonobese diabetic severe com-
bined immunodeficient  (NSG) mice whose diet was supplemented 
with appropriate doses of Dox. Upon reaching 1 cm3, the tumors 
were removed at autopsy and dissociated, and GFP expression of the 
cells was assessed by flow cytometry. Both EwS 3D culture–derived 
tumors displayed induction of GFP expression in vivo, with approxi-
mately 21% of EwS1 and 15% of EwS2 cells being GFP+ (Fig. 1D).
Next, we verified that mirRep145 allows separation of tumor cells 
based on their intrinsic miR-145 expression by quantitative poly-
merase chain reaction (qPCR) assessment of miR-145 transcripts in 
sorted GFP− and GFP+ subpopulations. Consistent with its mecha-
nism of action, expression of miR-145 was almost threefold lower in 
GFP+ than in GFP− cells (Fig. 1E). Immunohistochemistry (IHC) 
using anti-GFP antibody on tumor tissue sections revealed no GFP 
signal in control tumors but strong expression in a fraction of cells 
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Fig. 1. In vitro and in vivo implementation of the mirReporter assay. (A) Schematic overview of the experimental design (Dox, doxycycline; GFP, green fluorescent 
protein; IRES, internal ribosome entry site; LTR, long terminal repeat; Neo, neomycin; rtTA3, reverse tetracycline-controlled transactivator 3; PDX, patient-derived xenograft; 
TRE2, Tet response element 2; UBC, ubiquitin C promoter; 5′cap = ●—). (B) Representative confocal microscopy images of induced GFP (green) expression in HeLa- 
mirRep145 cells treated with Dox (1 g/ml, 48 hours) (bottom) compared to phosphate-buffered saline (PBS)–treated control cells (Dox−) (top) (40× objective; scale bar, 
50 m). (C) Representative confocal microscopy images showing decreased GFP expression (green) in Dox-treated HeLa-mirRep145 cells overexpressing miR-145 com-
pared to HeLa-mirRep145 cells overexpressing mock miRNA and let7a [middle: red fluorescent protein (RFP) expression (red); right: GFP expression (green); 40× objective; 
scale bar, 50 m]. (D) Fluorescence-activated cell sorting (FACS) based on GFP expression in mirRep145-bearing EwS1-PDX (top) and EwS2-PDX (bottom) cells. (E) Quan-
titative real-time polymerase chain reaction (qRT-PCR) assessment of mature miR-145 expression in GFP+ and GFP− subpopulations of EwS1-PDX carrying mirRep145 after 
in vivo induction, tumor dissociation, and cell sorting. (Mean ± SD values of three technical replicates are shown. Statistical analysis was done by unpaired t test; 
***P ≤ 0.001.) (F) Immunohistochemical assessment of GFP expression in tumor tissues of a EwS1-PDX-mirRep145–injected control mouse (Dox−) and a Dox-treated mouse 
(Dox+) (scale bars, 40 m; inset scale bar, 20 m).
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in tumors from Dox-fed mice (Fig. 1F and fig. S1H). Dox penetra-
tion of the tumor tissue appeared to be adequate, as GFP+ cells were 
observed throughout the tumor and not merely around blood vessels. 
miR-145 expression was significantly higher in both EwS1- and 
EwS2-derived PDXs compared to their corresponding in vitro cul-
ture models, confirming the ability of primary 3D culture–derived 
cells to generate more differentiated progeny in vivo (fig. S1I). On 
the basis of our earlier observations that miR-145 regulates the plu-
ripotency-associated gene SOX2 in EwS cells (18), we compared 
SOX2 expression between bulk EwS1 cells and their GFP+ and GFP− 
fractions. Consistent with our previous results, GFP+ cells expressed 
higher levels of SOX2 than their GFP− counterparts (fig. S1J).
Low miR-145 activity as a marker of primary EwS cells 
in a highly tumorigenic state
We then assessed miR-145high and miR-145low cell tumorigenicity 
in vivo. MirRep145-infected EwS1 and EwS2 3D culture–derived cells 
were transplanted beneath the kidney capsule of NSG mice, and 
tumor growth was monitored by ultrasonography weekly. Mice 
bearing tumors of about 1 cm3 were given Dox for 96 hours, after 
which they were euthanized and tumors were removed. Following 
dissociation and mouse cell depletion, tumor cells were sorted into 
GFP− and GFP+ subpopulations, which were then retransplanted 
beneath the kidney capsule of NSG mice. Unsorted bulk tumor cells 
(induced bulk, IB) from Dox-treated animals were transplanted into 
a third group of mice and tumor growth in all animals was moni-
tored by ultrasonography (Fig. 2A).
Self-renewal of GFP−, GFP+, and bulk cells from Dox-treated (IB) 
and untreated (control bulk) mice was assessed by clonogenic assays 
in which sphere formation was scored after 4 weeks of culture. Both 
EwS1 and EwS2 PDX–derived GFP+ cells displayed higher self- 
renewal than either batch of bulk or GFP− cells (Fig. 2B). Consistent 
with their higher self-renewal, EwS1 and EwS2 GFP+ cells were more 
tumorigenic than their GFP− counterparts (Fig. 2, C to G).
To verify mirRep145 stability, aliquots of cells derived from 
first-round xenografts, including IB, GFP+, and GFP− cells, were 
cultured in vitro in the presence of geneticin and Dox. The three cell 
populations retained resistance to neomycin, whereas only GFP+ and 
IB tumor–derived populations expressed GFP in response to Dox 
(fig. S2). MirRep145 therefore remained stably expressed and func-
tional throughout in vivo tumor growth, demonstrating the feasibility 
of using miR-145 expression as a functional reporter to isolate sub-
populations of cells with divergent tumorigenic capacity from a 
heterogeneous tumor cell population.
A dual-color mirReporter to monitor the evenness 
of cell infection
To ensure that GFP− and GFP+ subpopulations reflect endogenous 
differences in miR-145 expression rather than uneven cell infection, 
we generated a second mirReporter to monitor infection homogeneity. 
The RFP-puromycin vector (rPuro, described above) provides both 
an antibiotic selection marker and the means to track infected cells 
by monitoring RFP expression. We thus established a miR-145–
responsive dual-color reporter assay (Dual mirRep145) in which 
green fluorescence indicates miR-145 expression and red fluores-
cence reflects infection homogeneity (Fig. 3A).
Dual mirRep145 expression in HeLa cells (Fig. 3B) revealed that 
RFP expression was independent of Dox treatment, confirming suc-
cessful cell infection, and that GFP expression was induced upon 
Dox administration. Similarly, EwS1 and EwS2 cells harboring Dual 
mirRep145 expressed RFP and, upon treatment with Dox for 48 hours, 
initiated GFP while maintaining RFP expression (fig. S3A). Following 
removal of Dox, EwS1 and EwS2 cells lost GFP expression within 
10 days but retained RFP expression, indicating reporter stability.
EwS1 and EwS2 cells carrying Dual mirRep145 were sorted based 
on their RFP expression (fig. S3B) to select the most homogeneously 
infected cell population for in vivo tumor initiation assays (Fig. 3C). 
The selected Dual mirRep145–bearing EwS1 and EwS2 cells were 
transplanted beneath the kidney capsule of NSG mice, and follow-
ing tumor formation, mice were administered Dox as before. After 
tumor dissociation at autopsy, cells were assessed for GFP and RFP 
expression by flow cytometry (Fig. 3, D and E). EwS1 and EwS2 cells 
with comparable RFP expression were then sorted based on their 
GFP levels. The clonogenic and tumorigenic properties of sorted GFP− 
and GFP+ cells were assessed in vitro and in vivo, respectively. GFP+ 
cells displayed higher clonogenicity than their GFP− counterparts 
(Fig. 3F and fig. S3C), as well as greater tumor-initiating ability 
(Fig. 3G and fig S3, D to F). Our observations using Dual mirRep145 
were therefore consistent with those obtained using the single-color 
mirRep145.
Identification of candidate genes that underlie EwS 
aggressiveness and bear potential prognostic value
To gain insight into the mechanisms underlying the difference in 
GFP+ (miR-145low) and GFP− (miR-145high) EwS cell subpopulation 
behavior, we compared the transcriptome of primary GFP+ and 
GFP− cells derived from freshly dissociated EwS1-PDX and EwS2-
PDX carrying mirRep145 or Dual mirRep145. All cells sorted ac-
cording to GFP expression were included into a single statistical 
mode in which the covariate of interest was GFP expression, denoted 
as GFP+ and GFP−. The other covariates used for adjustment were the 
tumor origin (EwS1 or EwS2) and the type of reporter (mirRep145 
or Dual mirRep145). DEseq2 was used to fit the model and differen-
tially expressed genes were defined by |logFC| > 1 and a nominal 
P <0.01. Using these parameters, we found 55 and 29 significantly 
up- and down-regulated genes, respectively, in GFP+ compared to 
GFP− cells (tables S2 and S3). To address a possible link between 
miR-145 and EWS-FLI-1 expression levels, we compared differen-
tially expressed genes between GFP+ and GFP− EwS1 cells to those 
that displayed a change in expression upon EWSR1-FLI1 depletion 
by short hairpin RNA (shRNA) in the same model (23). However, 
the observation that the same EWS-FLI-1–dependent gene expres-
sion signature was enriched in both GFP+ and GFP− populations 
(fig. S4A) does not support the notion of variable EWS-FLI-1 ex-
pression between GFP+ and GFP− cells. In addition, expression of 
106 previously described EWS-FLI-1 direct target genes (23) was not 
found to be significantly different between GFP+ and GFP− cells 
(fig. S4B), indicating that their distinct behavior was not related to 
differences in EWSR1-FLI1 expression or function. Last, no signifi-
cant enrichment for direct miR-145 targets was identified among 
differentially expressed genes between GFP+ and GFP− cells (fig. S4, 
C and D), suggesting that the signatures distinguishing GFP+ from 
GFP− subpopulations are not merely the effect of miR-145 ex-
pression but the result of complex transcriptional programs that 
may define different cell phenotypes.
To determine whether these gene expression signatures may bear 
any prognostic value, we asked whether the significantly up- and 
down-regulated genes in the GFP+ subpopulation (miR-145low) are 
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Fig. 2. Primary EwS 3D cultures with low miR-145 expression display high clonogenic capacity in vitro and tumor-initiating capacity in vivo. (A) Schematic diagram 
of the experimental design of in vivo studies. (B) GFP+ (miR-145low) subpopulations of EwS1-PDX (left) and EwS2-PDX (right) have higher clonogenic capacity than their 
GFP− (miR-145high) counterparts (mean ± SD values of four technical replicates are shown). Control bulk and induced bulk (IB) cells were obtained from PDX-derived tumor 
tissues of control (drinking water devoid of Dox) and Dox-treated mice (2 mg/ml, 96 hours), respectively. (C) In vivo tumorigenicity of GFP+ and GFP− cells obtained from 
EwS1-PDX (right) and EwS2-PDX (left). (Average tumor volumes were measured weekly by ultrasonography. EwS1: IB, n = 5 mice; GFP−, n = 4 mice; GFP+, n = 6 mice. EWS2: 
IB, n = 3 mice; GFP−, n = 4 mice; GFP+, n = 6 mice. Mean ± SD values of technical replicates are shown. Primary tumors whose symbols are outlined in black are shown in 
Fig. 4G.) (D and E) Ultrasonograms of GFP− and GFP+ tumors from EwS1-PDX (D) and EwS2-PDX (E) 6 weeks after injection of cells beneath the kidney capsule (T, tumor 
tissue; K, kidney tissue; scale bars, 2 mm). (F and G) The GFP+ subpopulation of EwS1-PDX (F) and EwS2-PDX (G) gave rise to larger tumors than the GFP− subpopulation 
(mean ± SD values of technical replicates are shown). [One-way analysis of variance (ANOVA) was used to perform the statistical analysis of (B), (F), and (G), and two-way 
ANOVA was used for the analysis of (C); ns, not significant; *P ≤ 0.05; ***P ≤ 0.001; ****P ≤ 0.0001.]
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Dual-color mirReporter miR-145 vector (Dual mirRep145)
Fig. 3. A dual-color mirReporter allows monitoring cell infection homogeneity. (A) Diagram showing the dual-color mirReporter miR-145 construct (Dual mirRep145). 
(B) Representative confocal microscopy images showing Dox-induced (1 g/ml, 48 hours) GFP expression (green) in HeLa cells carrying the Dual mirRep145 (bottom) 
compared to PBS-treated control cells (top) [middle: RFP expression (red) indicating the distribution of Dual mirRep145 infection; 40× objective; scale bar, 50 m]. 
(C) Schematic illustration of the Dual mirRep145 assay design in vitro and in vivo. (D and E) FACS acquisition of RFP and GFP in Dual mirRep145 carrying EwS1-PDX (D) and 
EwS2-PDX (E) cells after in vivo induction of reporter expression [mice received Dox (2 mg/ml) for 96 hours before sacrifice and tumor dissociation]. (F) GFP+ EwS2-PDX–
Dual mirRep cells are more clonogenic than their GFP− counterparts. [Mean ± SD values of four technical replicates are shown. IB: dissociated tumor cells from mice 
treated with Dox (2 mg/ml) for 96 hours.] (G) Tumors derived from EwS2-PDX GFP+ cells grow faster than tumors originating from the corresponding GFP− cells (n = 5 mice 
per group). [One-way ANOVA test was used to perform the statistical analysis of (F) and two-way ANOVA was used for the analysis of (G); *P ≤ 0.05.]
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Fig. 4. Identification of EPHB2 as a candidate gene that underlies EwS aggressiveness with a potential prognostic value. (A) Heatmap of differentially expressed 
genes in the GFP+ subpopulation of EwS-PDXs (compared to GFP− counterparts). The Cox z values (and sign) indicate the strength of the positive correlation between the 
expression level of a gene and patient survival. (B) Kaplan-Meier curves showing overall survival of patients with high and low EPHB2 expression. (C) Relative EPHB2 
expression in IB, GFP+, and GFP− subpopulations of EWS1 and EWS2 PDX (mean ± SD values of three technical replicates are shown). (D) RNA in situ hybridization (ISH) 
assessment of EPHB2 expression in EwS-PDX tissues (scale bar, 25 m) and (E) in primary EwS tumors (scale bars, 50 m; arrows indicate ISH signals). (F) Distribution of local 
tumor– and metastasis-bearing mice following injection of the indicated cell subpopulations (IB, n = 5; GFP+, n = 6; GFP−, n = 4) with (G) representative pictures of primary 
tumors and matched livers (scale bars, 1 cm). (Corresponding primary tumor volume symbols are outlined in Fig. 2C. Photo credit: Tugba Keskin, CHUV.) (H) Representative 
H&E (hematoxylin and eosin)–stained sections of local tumors and matched liver metastases (scale bars, 50 m). (I) qRT-PCR assessment of EPHB2 transcripts in primary 
tumors and their matched liver metastases (mean ± SD values of three technical replicates are shown). [One-way ANOVA test was used to perform the statistical analysis 
of (C) and (I), log-rank (Mantel-Cox) was used for (B), and chi-square (Fisher’s exact test) was used for (F). ns, not significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.]
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predictive of survival for patients with EwS. We combined five dif-
ferent primary EwS microarray datasets into a single dataset con-
taining survival details of 129 patients. To assess putative predictive 
values of significantly down- and up-regulated genes in GFP+ cells on 
overall EwS patient survival, we performed univariate Cox analysis 
of the correlation between the gene expression level and survival 
duration. Such analysis produces a z value, which indicates the strength 
and sign of the correlation for significantly up- and down-regulated 
genes in the highly tumorigenic miR-145low EwS cells. We found 
that up-regulated genes had mostly positive z values (Fig. 4A), indi-
cating correlation between their expression and adverse prognosis, 
whereas the opposite was true of down-regulated genes. To validate 
these observations, Kaplan-Meier survival analysis was performed 
in the same cohort by comparing two clusters of patients with 
individual gene expression below (n = 65) and above (n = 64) the 
median value. A significant negative correlation was observed be-
tween expression of the up-regulated gene EPHB2 (P = 0.00191) and 
survival (Fig. 4B).
EPHB2 encodes a transmembrane RTK that binds ephrin ligands 
and mediates intercellular communication through bidirectional 
signaling (24). Several arguments support its functional implication 
in promoting EwS cell aggressiveness. First, its expression in GFP+ 
cells was about four times higher than in GFP− cells (table S2). 
Second, EwS patients bearing tumors with high EPHB2 expression 
levels have worse overall survival rates (Cox z = 4.102, Cox P = 4.09 × 
10−5, Kaplan Meier P = 0.00191) than patients with tumors expressing 
low levels of the gene (Fig. 4, A and B). Third, EPHB2 plays a 
well-established role in both maintaining cell pluripotency and pro-
moting carcinogenesis (25) and is implicated in tumor metastasis (26).
We therefore assessed EPHB2 expression in EwS1 and EwS2 
PDX-derived cell fractions and observed significantly higher ex-
pression of EPHB2 in GFP+ than in GFP− and IB cells in both 3D 
culture models (Fig. 4C). RNA in situ hybridization (ISH) analysis 
of EwS1 and EwS2 xenografts showed a marked difference in their 
EPHB2 expression pattern, with relatively diffuse expression in EwS1 
xenografts versus paucicellular expression in EwS2 (Fig. 4D). These 
observations reflect EPHB2 expression heterogeneity in EwS, in terms 
of both level and cell percentage, as illustrated by EPHB2 RNA ISH 
analysis of a cohort of 16 primary EwS patient samples (Fig. 4E 
and fig. S4E).
On the basis of the prognostic value of EPHB2 in patients with 
EwS and the notion that the major clinical determinant of EwS 
patient survival is their metastatic burden, we reasoned that EPHB2 
may be involved in EwS dissemination. Consistent with our hypoth-
esis, we observed a notable difference in metastatic spread among 
sorted cell populations. Following the second round of injection, 
tumors developed in all mice injected with GFP+ and IB cells from 
EwS1 PDX and in 75% of the mice injected with GFP− cells (Fig. 4F). 
However, whereas large liver metastases formed in 80 and 83.33% 
of mice injected with IB and GFP+ cells, respectively, none of the 
mice injected with GFP− cells developed visible metastases (Fig. 4F). 
This discrepancy did not appear to be due to differences in tumor 
growth at the site of injection because one EwS1 GFP+ tumor whose 
size was comparable to those of GFP− tumors was associated with 
large liver metastases (Figs. 4, G and H, and 2C). Expression of 
EPHB2 was elevated in the liver metastases derived from both IB 
and GFP+ tumors, as well as in GFP+ tumors at the site of injection. 
By contrast, it was low in IB tumors at the injection site and un-
detectable in GFP− tumors (Fig. 4I).
EPHB2, a candidate marker of EwS cells with self-renewing 
and metastatic properties
To determine its functional role in EwS self-renewal and tumor ini-
tiation, we partially depleted EwS1 cells of EPHB2 using lentiviral 
vectors bearing two different EPHB2-specific shRNAs (Fig. 5, A and B). 
Compared to controls, cells depleted of EPHB2 exhibited a dramatic 
decrease in spheroid formation in vitro (Fig. 5C) and a correspond-
ingly impaired ability to initiate tumor growth in vivo (Fig. 5, D to F). 
ISH and qPCR assessment of tumors that emerged from EPHB2- 
depleted cell xenografts revealed their expression of EPHB2 at levels 
comparable to those of control cells, suggesting that they originated 
from cells that had evaded EPHB2 depletion (Fig. 5, G and H). To 
circumvent the technical limitations inherent to shRNAs, we gener-
ated CRISPR-mediated EPHB2 knockout (KO) EwS1 cells using 
three different single guide RNAs (sgRNAs) targeting EPHB2. The 
resulting EPHB2-depleted EwS1 cells displayed markedly reduced 
clonogenicity (Fig. 6, A to C). To address the possible involvement 
of EPHB2 in pro-metastatic properties of GFP+ EwS1 cells, we 
addressed the invasiveness of EPHB2 KO cells in vitro, as assessed 
by Matrigel transwell assays. We observed that invasiveness was 
strongly impaired in the absence of EPHB2 (Fig. 6D).
To determine whether our functional observations reflect a 
general property of EwS, we interrogated the Cancer Cell Line 
Encyclopedia for EPHB2 expression levels in EwS cell lines and 
selected two, A673 and RD-ES, for further investigation based on 
their robust expression of the receptor. Both cell lines were grown 
as spheroids in ultralow attachment plates to mimic the primary 
models. After validation of its expression by FACS analysis (fig. S5, 
A and B), we depleted EPHB2 from both lines by shRNA and 
measured the ensuing changes in their clonogenicity and invasive-
ness in vitro. We observed a significant decrease in the clonogenicity 
and invasiveness of both cell lines upon EPHB2 depletion, support-
ing our findings in the primary EwS1 model (Fig. 6, E to H, and 
fig. S5, C to F).
In contrast to EwS1, EwS2 bulk and GFP+ cells formed only mi-
croscopic metastases (fig. S6, A to C). A possible explanation for the 
difference in behavior between EwS1 and EwS2 cells may lie in their 
origin: Unlike EwS1 cells, which were derived from a metastatic 
tumor to the lung following chemotherapy, EwS2 cells originated 
from a primary, untreated tumor and only few expressed EPHB2 
(Fig. 4D and table S1). We reasoned that if EPHB2 is involved in 
fueling the metastatic properties of EwS cells, enhancement of its 
expression in weakly metastatic primary tumor cells may promote 
their dissemination, similar to EwS1. Exogenous overexpression of 
EPHB2 in EwS2 cells (Fig. 7, A and B, and fig. S6D) did not alter 
their self-renewal or tumor-initiating ability (Fig. 7, C to F, and fig. 
S6E). In contrast, whereas EwS2 control cells did not form macro-
scopic metastases, EwS2 cells expressing exogenous EPHB2 formed 
multiple large metastases in several organs, particularly the liver, 
lung, contralateral kidney, and peritoneum (Fig. 7, G to J, and 
fig. S6, F and G). Careful histological examination revealed that 
control EwS2 cells were able to form a small number of micro-
metastases in the lung and kidney, often centered by blood vessels 
(Fig. 7J, left). However, in the absence of EPHB2 overexpression, no 
macro-metastases arose for the duration of the experiments. Together, 
our results indicate that EPHB2 promotes the metastatic properties 
of primary EwS cells, raising the possibility that pharmacological 
targeting of its signaling pathway may provide a candidate strategy 
to blunt EwS dissemination.







Keskin et al., Sci. Adv. 2021; 7 : eabf9394     2 July 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 16
APC fluorescence intensity 
     (EPHB2 expression)
Sample name Subset name  Median: APC
EwS1 shCnt Alive 129,449 
EwS1 sh1-E Alive 63,190 
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Fig. 5. EPHB2 depletion impairs tumor growth in vivo. (A) Relative EPHB2 expression of EwS1 3D culture infected with EPHB2-targeting shRNAs (sh1 EPHB2 and sh2 
EPHB2) compared to those in EwS1 control cells transduced with GFP-targeting shRNA (shCnt) as measured by qRT-PCR (mean ± SD, n = 3). (B) EPHB2 expression, as 
assessed by flow cytometry, in EwS1 3D cultures following shRNA-mediated EPHB2 depletion compared to EwS1 control cells (shCnt). (C) Clonogenic assay of EwS1 3D 
cultures depleted of EPHB2 (mean ± SD, n = 5). (D) Survival of mice injected with EwS1 3D cultures depleted of EPHB2 compared to mice injected with EwS1 control 3D 
culture (shCnt) (shCnt, n = 12; sh1 EPHB2, n = 11; sh2 EPHB2, n = 10). (E) EPHB2 depletion reduces the tumorigenic capacity of EwS1 3D culture (corresponding mouse 
numbers in each group are indicated in the graph bars). (F) Representative 3D ultrasonography reconstruction images of tumors at week 7 with corresponding tumor 
volumes (in cubic millimeters) below. (G) RNA ISH and (H) qRT-PCR assessment of EPHB2 transcript expression in tumors derived from EwS1-shCnt and EwS1-sh2 EPHB2 
xenografts indicate that the tumors initially depleted of EPHB2 regain its expression (scale bars, 50 m; arrows indicate ISH signals. qRT-PCR: mean ± SD, n = 3). [One-way 
ANOVA test was used to perform the statistical analysis of (A), (C), and (H); log-rank (Mantel-Cox) was used for (D); and chi-square (Fisher’s exact test) was used for 
(E). ns, not significant; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.]
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Sample name Median: APC 
EwS1 CR-Cnt 20,820 
EwS1 CR-E1 10,333 
EwS1 CR-E2 8873 

















Sample name Median: APC
A673 shCnt 46,435 
A673 sh1 EPHB2 23,045 
A673 sh2 EPHB2 31,041 
















































































Fig. 6. EPHB2 depletion reduces clonogenicity and invasiveness of EwS cells. (A) Relative EPHB2 expression of EwS1 3D culture infected with EPHB2-targeting sgRNAs 
(CR-E1, CR-E2, and CR-E3) compared to EwS1 control cells (CR-Cnt) as measured by qRT-PCR (mean ± SD values of three technical replicates are shown). (B) EPHB2 expres-
sion, as assessed by flow cytometry, in EwS1 3D cultures following sgRNA-mediated EPHB2 depletion in (A). (C) Clonogenic and (D) transwell-invasion assays for EwS1 
tumor 3D cultures depleted of EPHB2 (CR-E1, CR-E2, and CR-E3) compared to control cells (CR-Cnt) (mean ± SD values of four and three technical replicates are shown for 
clonogenic and invasion assays, respectively). (E) qRT-PCR and (F) FACS analysis of EPHB2 expression in the EwS A673 cell line transduced with EPHB2 targeting shRNAs 
(sh1 EPHB2 and sh2 EPHB2) compared to control cells (shCnt). (G) Clonogenic and (H) transwell-invasion assays for A673 cells depleted of EPHB2 (sh1 EPHB2 and sh2 
EPHB2) compared to control cells (shCnt) (mean ± SD values of four and three technical replicates are shown for clonogenic and invasion assays, respectively). [One-way 
ANOVA test was used for statistical analysis of (A), (C), (D), (E), (G), and (H); **P ≤ 0.01; ****P ≤ 0.0001.]
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Sample Name % EPHB2- % EPHB2+
EwS2 Cnt 99.7 0.31
EwS2 E-OE 2.21 97.8
EPHB2-
IH
       Tumor area = 8.58 × 10³ µm²
 EPHB2 OE #1  EPHB2 OE #2
EwS2-PDX
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Fig. 7. EPHB2 overexpression increases EwS2 3D culture invasiveness. (A) qRT-PCR and (B) FACS assessment of EPHB2 expression in EwS2 cells overexpressing EPHB2 
(EPHB2 OE) compared to control cells (Cnt). (C) Clonogenic assay of EwS2 EPHB2 OE and Cnt cells (mean ± SD values of five technical replicates are shown). (D) Survival of 
mice injected with EwS2 EPHB2 OE or EwS2 control 3D cultures (Cnt) (Cnt, n = 7; EPHB2 OE, n = 8). (E) Percentage of mice developing tumors following injection with the 
indicated EwS2 3D cultures (Cnt, n = 7; EPHB2 OE, n = 8). (F) Representative 3D sonography reconstruction images of EwS2 EPHB2 OE and EwS2 Cnt tumors. (G) Overex-
pression of EPHB2 significantly increased metastasis of EwS2 cells (Cnt, n = 7; EPHB2 OE, n = 8). (H) The total area of EwS2 metastases per mouse increased as a result of 
EPHB2 overexpression (mean ± SD. Cnt, n = 7; EPHB2 OE, n = 8). (I) Mice injected with EwS2 EPHB2 OE had a significantly higher metastatic burden than mice injected with 
control EwS2 cells (Cnt, n = 7; EPHB2 OE, n = 8). (J) Representative H&E sections of lung and liver metastases in mice injected with EwS2 EPHB2 OE compared to animals 
injected with control EwS2 cells (scale bars, Cnt: 200 m, 3 mm; EPHB2 OE#1: 200 m, 4 mm; EPHB2 OE#2: 200 m, 5 mm). [One-way ANOVA test was used to perform the 
statistical analysis of (A), (C), and (H); log-rank (Mantel-Cox) was used for (D); and chi-square (Fisher’s exact test) was used for (E), (G), and (I). ns, not significant; *P ≤ 0.05, 
**P ≤ 0.01, ****P ≤ 0.0001.]
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DISCUSSION
Elucidation of the biological properties of cells responsible for tumor 
initiation, maintenance, and progression is key for the development 
of effective cancer therapies. However, in most cancer types, identi-
fication of these cells has been limited by reliance on predefined, 
largely nonspecific cell surface markers (27). Although helpful in 
uncovering subpopulations of cells enriched in those endowed with 
pluripotency and tumor-initiating ability, currently used markers 
fall short of accurately identifying the cells that actually display such 
properties. To overcome these limitations and isolate cells that rep-
resent the driving force of tumorigenesis, we developed a functional 
reporter assay, using as a model, EwS, in which a small fraction of 
cells display pluripotency and hold at least part of the responsibility 
for tumor initiation and phenotypic heterogeneity (21, 22).
In EwS (16–18), and probably most pediatric cancers (28–32), 
cellular heterogeneity is generated primarily by epigenetic forces, 
which include histone modifications, DNA methylation, and miRNA 
expression. Because they are key players in the fine-tuning of cancer 
cell phenotypes by regulating pluripotency and differentiation, 
miRNAs are well suited to generate powerful candidate reporter 
systems. The level of their expression may not only be a reliable re-
flection of cell phenotypes that are pertinent to aggressive or indolent 
tumor behavior but also associate with gene expression networks 
that contribute to that behavior and help identify the relevant genes. 
On the basis of the dynamics of its expression according to the 
degree of tumor cell pluripotency or differentiation, we selected 
miR-145 to generate a reporter designed to reflect a spectrum of 
cancer cell phenotypes and identify those of interest. Using the re-
porter to target cells with low miR-145 expression in EwS, we identi-
fied highly tumorigenic subpopulations with metastatic properties.
Of the small number of deregulated genes shared by miR-145low 
cell subpopulations from two independent primary tumors, EPHB2 
appeared immediately relevant, as its expression is associated with 
poor prognosis in EwS according to existing databases. The expres-
sion pattern was divergent between our two 3D culture models, being 
relatively diffuse in EwS1, which was derived from a metastatic tumor, 
but limited to only a small number of cells in EwS2, obtained from a 
primary tumor. Reminiscent of their tumors of origin, EwS1 formed 
macroscopic metastases following subcapsular renal injection of 
NSG mice, whereas EwS2 formed micrometastases composed of 
only a small number of cells, preferentially located around blood 
vessels in the lung and contralateral kidney in a fraction of mice. 
Overexpression of EPHB2 in EwS2 cells drove them to form macro-
metastases in several organs, providing a clear indication that EPHB2 
expression participates in driving EwS metastatic proclivity.
EPHB2 expression is associated with the development and pro-
gression of diverse tumor types (33–35) and may facilitate metastasis 
by enhancing angiogenesis (36), modifying tumor cell adhesion and 
migration (35, 37) and promoting invasion (38). Our present obser-
vations raise the possibility that the level of EPHB2 expression among 
metastatic tumor cells may determine their emergence from dorman-
cy and/or adaption to the newly colonized microenvironment.
Our study suggests that diverse and complementary approaches 
may be required to dissect tumor heterogeneity at a functional level. 
Single-cell studies of EwS suggested that fluctuations in EWSR1-FLI1 
expression levels might underlie diverse biological properties among 
tumor cell subpopulations, including proliferation and metastatic 
proclivity (39, 40). These observations, coupled to the notion that 
EWSR1-FLI1 is a miR-145 target (18), would be consistent with 
variable EWS-FLI-1 expression levels as an explanation for the dif-
ferences in tumorigenic behavior of GFP+ and GFP− populations 
within our primary models. However, our comparative gene expres-
sion analysis of EWS-FLI-1 targets and GFP+/GFP− signatures did 
not support this hypothesis. The absence of a clear miR-145 target 
gene signature in the differential transcriptional profile between 
GFP+ and GFP− cells suggests that complex transcriptional programs, 
to which miR-145 expression is associated, govern the biological 
properties of these subpopulations and underlie their phenotypes. 
In support of this notion, expression of the miR-145 target 
SOX2, an important player in cell pluripotency, was elevated in 
GFP+ cells. EPHB2, on the other hand, is not a miR-145 target but 
rather an effector component of the expression profile of EwS cells 
with low miR-145 levels, which in turn reflects a cellular phenotype 
associated with high metastatic proclivity.
A potential limitation of the present study is the use of only two 
primary tumor-derived EwS 3D cultures. Generation of primary 3D 
cultures from sarcomas, and EwS in particular, has been challenging, 
which explains the small number of currently available 3D EwS cul-
tures. However, we confirmed our observations using two established 
cell lines grown as spheroids. Another limitation is the current lack 
of pharmacological inhibitors of the EPHB2 receptor, which re-
stricted our assessment of the effect of its inhibition to observations 
based on its shRNA-mediated depletion. Given that EPHB2 is an 
RTK, however, development of pharmacological inhibitors should 
be possible.
These limitations notwithstanding, we have shown that combin-
ing a miRNA-based functional reporter system with primary tumor 
3D culture technology provides a powerful and reliable method to 
isolate and characterize tumor cells that display aggressive behavior, 
including the formation of metastasis. MirRep145 allowed us to 
identify EPHB2 as a mediator of EwS metastasis that can be used 
both as a predictor of tumor behavior and as a potential therapeutic 
target to eliminate the most aggressive cells. The instructive role of 
miR-145 in cell fate transitions during cancer initiation and pro-
gression supports our strategy as an unbiased approach to explore 
and target tumor heterogeneity in diverse cancer types without the 
requirement of a predefined marker.
MATERIALS AND METHODS
Plasmid construction
Tet-On inducible mirReporter expression vectors were constructed 
using the Gateway LR Clonase II Enzyme Mix (Thermo Fisher 
Scientific). pINDUCER20 (Addgene, #44012) and pENTR/D- 
TOPO (Thermo Fisher Scientific) were the destination and entry 
vectors, respectively.
The coding sequence of enhanced GFP (EGFP) was amplified by 
PCR using pcDNA3-EGFP (Addgene, #13031) as template and 
EGFP-F and EGFP-R primers. The amplified EGFP cDNA sequence, 
which included a 3´UTR containing three miR-145 recognition sites, 
was cloned into the Bst BI and Mlu I restriction sites of the pLIV 
lentiviral vector (23). An EGFP cDNA containing five miR-145 rec-
ognition sites was subsequently generated by inserting two more 
miR-145 target sequences (oligo DNA A and oligo DNA B; table S4) 
into the Mlu I and Bam HI cloning site in the pLIV-EGFP vector 
containing the three miR-145 target sequence repeats. The resulting 
sequence was PCR-amplified using the primer pairs TOPO-F 
and TOPO-R (table S4), and the PCR product was cloned into the 
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pENTR/D-TOPO plasmid for subsequent pInducer20 gateway 
cloning. The target sequence of hs-mir-145-5p was obtained from 
the online tool mirbase.org (MIMAT0000437). MirReporter-Control 
was created by replacing the hs-mir-145-5p target sequence with the 
3´UTR sequence of glyceraldehyde-3-phosphate dehydrogenase 
[National Center for Biotechnology Information (NCBI) Reference 
Sequence: NM_001256799.3; sequence position: 1186-1313].
The dual-color mirReporter–miR-145 vector was obtained by 
replacing the neomycin cassette and the internal ribosome entry site 
sequence with the coding sequence of rPuro and the EF (elongation 
factor)-1 promoter, respectively. The double-stranded synthetic 
DNA fragment (IDT) containing the rPuro coding sequence taken 
from the pLV-mir-control plasmid (catalog no. mir-p000, Biosettia) 
was inserted into the Nde I and Ssp I cloning site of mirReporter-145. 
Next, a DNA synthetic fragment (IDT) bearing the EF-1 promoter 
sequence was cloned into the Nde I and Spf I site. The synthetic DNA 
fragment sequences are available upon request.
Establishment of primary tumor 3D cultures and cell culture
EwS tumor samples were obtained from consenting patients with the 
approval of the ethics committee of the Canton de Vaud (Authori-
zation No. 260/15). Primary tumor 3D cultures were established 
following immediate mechanical and enzymatic dissociation of the 
tumor samples. Red blood cells (RBCs) were removed using RBC 
lysis buffer (Miltenyi Biotec), and tumor cells were resuspended in 
Iscove's modified Dulbecco's medium (Gibco) containing KO serum 
(20%; Gibco), recombinant human EGF (10 ng/ml; Invitrogen), 
recombinant human FGF (10 ng/ml; Invitrogen), and penicillin- 
streptomycin (1%; Gibco) in ultralow attachment flasks (Corning). 
Once established, tumor cell 3D cultures were disrupted into single- 
cell suspensions manually with a P1000 pipette, and early passages 
were cryopreserved. EwS1 and EwS2 cultures were passaged every 7 
and 4 days, respectively. In this study, EwS1 and EwS2 3D cultures 
ranged between passages 4 to 15 and 15 to 30, respectively.
HeLa cells [American Type Culture Collection (ATCC)] and 
A673 cells (ATCC) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco) whereas RD-ES cells (ATCC) were grown 
in RPMI (Gibco) supplemented with fetal bovine serum (FBS) 
(10%, PAN-Biotech) and penicillin-streptomycin (1%; Gibco). 
Human embryonic kidney (HEK) 293T cells (ATCC) were cultured 
in DMEM (Gibco) supplemented with FBS (10%; PAN-Biotech), 
MEM nonessential amino acid (Gibco), and penicillin-streptomycin 
(1%; Gibco). Cell cultures were maintained at 37°C in humidified, 
5% CO2 chambers. Spheroids of A673 and RD-ES cells were grown 
in ultralow attachment plates (Corning) and used in clonogenic and 
Matrigel-invasion assays.
Lentiviral infection and in vitro induction
For lentiviral production, HEK 293T cells (ATCC) were transfected 
using FuGENE 6 Transfection Reagent (Promega). pMD2G (Addgene, 
#12259) and pCMV∆R8.74 (Addgene, #12263) vectors were used as 
envelope and packaging plasmids, respectively. Lentiviral harvest 
was performed using Lenti-X Concentrator (TAKARA). Single-cell 
suspensions from primary EwS 3D cultures were infected with lenti-
virus expressing mirReporter-Control, mirReporter–miR-145, or 
dual-color mirReporter–mir-145. HeLa cells were infected for over-
expression of mock-miRNA-rPuro (catalog no. mir-p000, Biosettia), 
mir-let7a-rPuro (catalog no. mir-p001, Biosettia), and mir-145-rPuro 
(catalog no. mir-p116, Biosettia). Transduced cells were selected by 
geneticin (1 mg/ml; Gibco) and puromycin (1 g/ml; Invivogen) for 
7 and 3 days, respectively, before further analysis.
EPHB2 depletion was achieved using pLKO.1 lentiviral shRNAs 
purchased from the RNAi Consortium (sh1 ref.: TRCN0000006423; 
sh2 ref.: TRCN0000006425), and sgRNAs targeting EPHB2 (CR-E1, 
CR-E2, and CR-E3) were designed using the online CRISPR tool box 
CHOPCHOP (41) and cloned into the lentiCRISPRv2 vector. sgRNA 
target sequences were as follows: CR-E1: ACCAAGTTTATCCGG-
CGCCGTGG; CR-E2: AGAAGACACGCACGGCGATGAGG; and 
CR-E3: GTCCGGCTGGGACCACGACA-GGG. In EPHB2 knock-
down studies, control cells were infected with shRNA or sgRNA 
sequences targeting the GFP transcript (GCAAGCTGACCCT-
GAAGTTCAT). For EPHB2 overexpression, a plasmid carrying 
EPHB2 cDNA sequence under the EF-1 promoter (catalog no. 
EX-E2379-Lv156) and its control plasmid expressing EGFP cDNA 
(catalog no. EX-EGFP-Lv156) were purchased from GeneCopoeia.
Light and fluorescent microscopy
Primary EwS 3D cultures were treated with Dox (100 ng/ml) 
(Sigma-Aldrich) for 48 hours and cultured for 10 days. Represent-
ative images were acquired using a Nikon Eclipse TS100 inverted 
epifluorescence microscope with ultraviolet lamp and filters set 
to 488 and 561 nm to detect GFP and RFP, respectively. HeLa 
cells seeded on coverslips (10 mm, VWR) were treated with Dox 
(1 g/ml) for 48 hours. After fixation (4% formaldehyde, 10 min at 
room temperature) and mounting, slides were imaged by Zeiss 
Confocal Fluorescent Microscope LSM710 at 40×/1.30 numerical 
aperture oil immersion.
RNA extraction and real-time PCR
Total RNA extraction was performed using a miRCURYTM RNA 
Isaltion Kit (Exiqon). Five hundred nanograms of RNA template was 
used for cDNA synthesis (miRCURYTM LNA Universal RT miRNA 
PCR, Universal cDNA Synthesis Kit II, Exiqon).
Real-time PCR amplification was done using Power SYBR Green 
PCR Master Mix (Applied Biosystems) in a QuantStudio 5 System 
instrument (Thermo Fisher Scientific). PCR conditions included an 
initial holding period at 50°C for 2 min and 95°C for 10 min fol-
lowed by 95°C for 15 s and 60°C for 1 min for 40 cycles. RNA LNA 
(Exiqon) primer sets were used for hsa-mir-145-5p and endogenous 
control Snord49a amplification. The EPHB2 primer pair was selected 
according to PrimerBank (http://pga.mgh.harvard.edu/primerbank) 
(PrimerBank ID: 111118977c1; table S4). Ribosomal protein lateral 
stalk subunit P0 transcript expression was used as the endogenous 
control (table S4). Relative quantitation of gene expression data was 
conducted according to the 2−Ct method.
Flow cytometry
After 48 hours of Dox treatment, the culture medium of the induced 
cells was replaced with fresh medium and cells were kept in culture 
for 10 days [after 48-hour induction, halting Dox treatment at D0 
(Day 0) and verifying GFP expression at D2, D5, and D10]. To assess 
EPHB2 levels, cells were labeled with APC (AlloPhycoCyanin) Mouse 
Anti-Human EPHB2 (BD Pharmingen). APC Mouse Immuno-
globulin G1 (IgG1), K isotype antibody was used for control cell la-
beling. Calcein violet 450  acetoxymethyl (AM) (Thermo Fisher 
Scientific) labeling dye was used to detect live cells. The fluorescence 
intensity of GFP, violet AM, and APC was acquired by a Gallios 
(B43618, Beckman Coulter) cytometer with FL1, FL9, and FL6.
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In vivo experiments, cell sorting, and tumor monitoring
All animal experiments were approved by the Animal Experimentation 
Ethics Committee of the Veterinary Service of the Canton of Vaud 
(Etat de Vaud, Service Vétérinaire), under authorization number 
VD2488.1. Ten thousand cells derived from dissociated EwS1 and 
EwS2 3D cultures in 20 l of medium were injected beneath the renal 
capsule of 4- to 8-week-old, female NSG-KO mice. Tumor growth 
was monitored by ultrasound imaging using a 40-MHz probe and 
the Vevo 2100 ultrasound machine (VisualSonics). Tumor volumes 
were calculated by V = 4/3 p(Dd × Ds × Dt)/8 (Dd: tumor height; 
Ds: tumor length in long axis; Dt: tumor length in short axis), and 
animals were euthanized when the tumor volume reached 1 cm3. 
Mice received Dox (2 mg/ml) (Sigma-Aldrich) and 5% sucrose 
(Sigma-Aldrich) in drinking water starting 96 hours before sacrifice. 
After dissection, tumor fragments removed from each tumor bulk 
were fixed in 4% paraformaldehyde and processed for hematoxylin 
and eosin (H&E) staining and RNA ISH. The remaining tumor tis-
sue was dissociated using a tumor dissociation kit (Miltenyi Biotec) by 
gentleMACS dissociator (Miltenyi Biotec). RBCs were removed by 
RBC lysis buffer (Miltenyi Biotec), and human tumor cells were en-
riched by depletion of mouse cells using a mouse cell depletion kit 
(Miltenyi Biotec). Before sorting GFP+ and GFP− cell populations by 
a Moflo Astrios EQ cell sorter (Beckman Coulter), dissociated tu-
mor cells were treated with Calcein AM (Thermo Fisher Scientific) 
live-cell labeling dye and 4′,6-diamidino-2-phenylindole (DAPI) 
(Biotium) to remove dead cells. The sorted GFP+ and GFP− cell 
populations were injected beneath the renal capsule of NSG mice, 
and tumor growth was monitored by ultrasonography weekly.
Clonogenic and invasion assay
Spheroids generated from freshly dissociated patient-derived xeno-
grafts (PDX) and EwS cell lines A673 and RD-ES were sorted as 
single cells into 96-well plates (ultralow attachment; Corning) at 
one cell per well using a Moflo Astrios EQ cell sorter (Beckman 
Coulter). Calcein AM (Thermo Fisher Scientific) and DAPI 
(BIOTIUM) were used for live-cell detection. Sphere formation was 
monitored and scored 4 weeks after sorting.
Invasion assays were done according to the manufacturer's in-
structions (Corning Biocoat Matrigel Invasion Chamber). Briefly, 
50,000 single cells were cultured in serum-free medium in the upper 
chamber of the transwell, whereas the lower chamber was filled 
with medium supplemented in KO serum. After 48 hours of cul-
ture, the cells in the upper chamber were removed and those in 
the lower layer of insert membranes were stained, and the mem-
branes were mounted onto glass slides. Cells were counted using a 
Fiji-ImageJ program.
IHC and RNA ISH
Formalin-fixed, paraffin-embedded PDX tumors and mouse or-
gans were sliced into 5-m sections and subjected to standard H&E 
staining or IHC to detect GFP expression. RNAscope technology 
[Advanced Cell Diagnostics (ACD)] was used for RNA ISH accord-
ing to the manufacturer’s instructions as described previously (42). 
Briefly, tissue sections on slides were baked for 1 hour at 60°C, 
deparaffinized, and dehydrated. The tissues were pretreated with 
hydrogen peroxide for 10 min at room temperature and with target 
retrieval reagent for 15 min at 98°C. Protease Plus was then applied 
for 30 min at 40°C. EPHB2 probe (ACD) was hybridized for 2 hours 
at 40°C, followed by signal amplification. Tissue was counterstained 
with Gill’s hematoxylin followed by mounting with VectaMount 
mounting media (Vector Laboratories). Images were taken with 
a Hamamatsu NanoZoomer S60 Digital slide scanner, at ×40 
magnification.
Analysis of RNA sequencing data and relevance to survival
RNA sequencing (RNA-seq) library preparation was performed 
according to the Illumina TruSeq protocol by IGE3 genomic plat-
form of University of Geneva. RNA-Seq was performed using 
HiSeq 4000 Illumina.
Reads were aligned to the human genome (NCBI-hg38) using 
hisat2 with default parameters. Gene-level counts for each sample 
were obtained with featureCounts against the hg38 RefSeq tran-
scriptome. DeSeq2 was used to determine genes differentially ex-
pressed between GFP+ and GFP− cells, correcting for tumor 3D 
culture of origin and type of reporter. Differentially expressed genes 
were defined by |logFC| > 1 and nominal P value < 0.01.
Five microarray datasets of primary EwS [GEO accession num-
bers: GSE12102 (43), GSE17618 (44), GSE34620 (45), and GSE63155 
and GSE63156 (46)] were combined into a single dataset using the 
brainarray CDFs (Chip Definition Files) and ComBat from the sva 
package to remove batch effects. Normalization was performed with 
the SCAN.UPC package that provides a convenient interface for nor-
malization with alternative CDFs and batch correction with ComBat.
For the differentially expressed genes for which expression data 
from the integrated dataset were available, we performed two types 
of survival analysis: Cox univariate analysis using expression as a 
continuous variable and Kaplan-Meier analysis after dividing the 
samples in two groups. [The median expression of EPHB2 was used 
as the cutoff to divide the patients (n = 129) into high (n = 64) and 
low (n = 65) expressors.]
The heatmap in Fig. 4A shows, for all differentially expressed 
genes for which Cox univariate analysis was performed, the loga-
rithmic fold change in the two primary tumor 3D cultures [differ-
ence in log2(RPKM + 1) between GFP+ and GFP− cells, averaged 
over all experiments on each tumor 3D culture] and the Cox z value. 
Up-regulated (down-regulated) genes are ordered by decreasing 
(increasing) Cox z.
Overlaps of differentially expressed genes with gene lists obtained 
from the literature or databases were statistically assessed using 
Fisher’s exact test, with all genes analyzed by DeSeq2 as the universe. 
The list of direct EWS-FLI1 targets was obtained from (42), while 
predicted targets of miRNAs were obtained from TargetScan through 
the targetscan.Hs.eg.db Bioconductor package. For miRNA targets, 
no overlap was significant after correcting for multiple testing 
(Benjamini-Hochberg false discovery rate).
Statistical analysis and software used
GraphPad Prism (version 7) program was used to generate graphs 
and to perform one-way analysis of variance (ANOVA), Student’s 
t test, two-way ANOVA, and log-rank (Mantel-Cox) test analyses. 
Analyses of flow cytometry acquisition data were done by FlowJo 
(version 10) program. qRT-PCR data were collected by QuantStudio 
design and analyses software (version 1.4.2). IHC and RNA ISH im-
ages were analyzed by AperioImageScope (v12.1.0.5029) and NDP.
View2 Viewing software (U12388-01). biorender.com and Adobe 
illustrator (2020) programs were used to create the figures. Bio-
informatic analysis was performed with R and its packages “survival,” 
“SCAN.upc” (47), “sva,” “Rsubread” (48), and “DESeq2” (49).
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SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/27/eabf9394/DC1
View/request a protocol for this paper from Bio-protocol.
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